Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by RjM2018on Jun 05, 2020 10:30am

223 Views

Post# 31116168

RE:RE:Why IS THIS STOCK FALLING!

Hi Mott,

I understand the temptation to want to compare ATE's recent results with published results for Naproxen. However, we would be comparing apples to organges, this was stressed on the call by the CMO. Meta analysis of this nature are imperfect by any stretch of the imagination and incredibly prone to researcher bias (1,2). Hence the need for a dynamic phase 3 trial for direct head-to-head comparison to Naproxen in a controlled setting. It seems to me like this is a cart before the horse scenario - based on your thinking - the market is pricing this stock not on the current great phase 2 results but rather on a hypothetical comparison to Naproxen - a question we will know the answer to after phase 3.

Further, what it interesting is there is variablity in the WOMAC scoring system used across clinical trials which further confounds potential meta-analysis comparison (3). ATE used a 500 point Likert scale in theirs (4: slide 14)

That being said, a member on this board (backtobaystreet) created a table comapring results from various studies highlighted here: https://imgur.com/ZdDqL7m

Sources:
(1)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868184/
(2)https://www.bmj.com/content/344/bmj.d7762
(3)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373321/
(4)https://antibethera.com/wp-content/uploads/2020/06/Antibe-Investor-Presentation-June-2020.pdf